1. Introduction {#sec0005}
===============

Coronavirus infection had spread around the world at high speed, to rapidly became a pandemic \[[@bib0005]\]. On March 11, 2020, the world health organization (WHO) officially declares this disease as a pandemic, with an exponential increase in the number of cases, with social and economic implications \[[@bib0010],[@bib0015]\]. Clinical predictors of mortality have been described in patients with underlying cardiovascular and metabolic diseases such as hypertension, diabetes, and hypothyroidism \[[@bib0020],[@bib0025]\]. There is a growing interest in the study of clinical factors of severity and predictors of mortality that guide us to which patient special attention should be paid and thus optimize to the maximum the health systems of these patients at risk, however, the history of brain disease vascular is poorly studied \[[@bib0030],[@bib0035]\]. A systematic review by Aggarwal et al. in 2020 shows an increased risk of a severe form disease i.e. **COVID-19** secondary to infection by the SARS-COV 2 virus, without conclusive results in other clinical outcomes \[[@bib0085]\]. Multiple reports have linked COVID19 patients and the development acute ischemic stroke \[[@bib0105]\]. History of stroke had been associated with an increased risk of a new ischemic stroke. Few articles have dedicated the real value that the history of cerebrovascular disease (ischemic or hemorrhagic) has in the subsequent development of this disease, so this systematic review and meta-analysis is conducted to summarize the existing evidence on the impact on mortality of history of previous cerebrovascular disease in patients suffering from the disease known as COVID-19 \[[@bib0105]\].

2. Methods {#sec0010}
==========

A systematic review and meta-analysis was performed in accordance with the PRISMA Guidelines.

2.1. Search and inclusion criteria {#sec0015}
----------------------------------

A search for randomized clinical trials is performed in the following databases: PUBMED (until May 2020); Cochrane Injuries Group Specialized Registry (until May 2020); The Cochrane Central Register of Controlled Trials (The Cochrane Library) (until May 2020); MEDLINE (Ovid) until May 2020; EMBASE (Ovid); PubMed \[<http://www.ncbi.nlm.nih.gov/sites/entrez>\] (May 2020); in addition to the reference list of included studies and other relevant data in addition to potentially eligible studies. The search was constructed using Medical Subject Heading (MeSH) terms and descriptors, all combined with Boolean operators. The search was not limited by dates or languages.

2.2. The search strategy was as below {#sec0020}
-------------------------------------

("Stroke" OR "cerebral ischemia" OR "ischemic stroke" OR "cerebrovascular disease") AND ("SARS-COV2 infection "OR" coronavirus "OR" COVID19 "OR" novel coronavirus") AND ("mortality "OR" dead") NOT ("aneurysmal subarachnoid hemorrhage" OR "Arteriovenous malformation bleeding" OR "traumatic brain injury" OR "traumatic ischemia")

After applying the search strategy in databases and removing duplicates and extracting full text of potentially eligible studies, it is carried out independently, the studies included in the meta-analysis are chosen, disagreements were resolved by consensus. Case series, prospective and retrospective observational studies evaluating mortality from COVID19 including patients with a clinical history of cerebrovascular disease were included.

2.3. Assessment of quality and risk of bias {#sec0025}
-------------------------------------------

The outline followed was according to the recommendations of meta-analysis and systematic reviews of the PRISMA statement, for the presentation of systematic reviews, meta-analyzes, and the Cochrane manual of systematic reviews and meta-analyzes. The quality of the included studies was assessed through the Newcasttle Ottawa Scale (NOS), according to their score in low quality (less than 4 points), Moderate-High (5 points), High (6 and 7 points). \[[@bib0040]\]The risk of bias assessment was performed using the ROBINS-I scale that evaluates the risk of bias in \"Low risk\", \"Moderate risk\", \"High risk\", \"Critical risk\". in the domains \"selection\", \"intervention\", \"missing data\", \"confusion\", \"measurement of results\", \"report\" and an overall evaluation expressed in \"global risk of bias\" \[[@bib0045]\].

2.4. Extraction, management and statistical analysis of the data {#sec0030}
----------------------------------------------------------------

The following data were extracted: COVID 19 patients with a history of cerebrovascular disease and mortality. Authors were contacted for missing data. Statistical analysis was performed using relative risk using the Mantel-Haenszel methodology for dichotomous variables with a randomized effect analysis model calculated using Review Manager 5.3 software. Heterogeneity was assessed by calculating I^2^, with high heterogeneity of the studies included in the analysis being above 60 %.

3. Results {#sec0035}
==========

3.1. Selection of studies {#sec0040}
-------------------------

The selection process of the studies was based on the PRISMA foundations as shown in [Fig. 1](#fig0005){ref-type="fig"} . After carrying out the systematic search for information following our strategy, 213 bibliographic citations were identified, of which 30 were considered potentially eligible based on title or abstract, or both, and the full texts were obtained. After a full-text review, 20 studies were deemed eligible, 13 were not included as these were not meeting inclusion criteria ([Fig. 1](#fig0005){ref-type="fig"}), and a total seven articles met the inclusion criteria for the review. [Table 1](#tbl0005){ref-type="table"} summarizes the characteristics of the included studies. (Supplementary material) The quality of included studies was assessed and it was found that three of the included studies obtained a score of five, considering that 42.28 % of the included studies were of moderate quality, three studies (42.28 %) were of moderate high quality obtaining a score of 6/7 and the one study obtained a score of 7/7, considering it the only included study of high quality (see [Table 2](#tbl0010){ref-type="table"} ). The risk of bias was evaluated for the different studies chosen using the ROBINS-I tool. It was found that overall, a low risk of bias was obtained in 71.43 % of the included studies and the bias of missing data is the one that presented the highest risk of bias with high risk of bias in 33 % of included studies ([Fig. 2](#fig0010){ref-type="fig"} ). Seven studies were chosen for the final analysis, involving 3244 patients with SARS VOC 2 Disease (COVID19) of which 198 had history of cerebrovascular disease. Meta-analysis of the data was performed, the study finding were, an increase in mortality in patients with a past history of cerebrovascular disease compared to those with a different medical history or those without any disease (OR 2.78 95 % CI \[1.42--5.46\] p = 0.007; I^2^ = 49 %) with adequate heterogeneity (see [Fig. 3](#fig0015){ref-type="fig"} ). The presence of publication bias was evaluated using the Egger test in a funnel plot with an adequate symmetry, indicating that there was no publication bias, however, due to the low number of included studies, we could not rule out or confirm the presence of bias ([Fig. 4](#fig0020){ref-type="fig"} ).Fig. 1Process of study selection -- Flow chart of our search strategy and inclusion and exclusion criteria.Fig. 1Table 1Summary of the characteristics of the included studies.Table 1StudySampleAgeOutcomes assessedNumber of patients with a history of CVDFollow-upChen et al 2020 \[[@bib0050]\]11368 years old (37−88)Mortality\
Severity\
Complications (heart failure, kidney failure, sepsis)10In HospitalGrasselli et al 2020 \[[@bib0055]\]159163 years old (56−70)Mortality\
Severity\
Complications (heart failure, kidney failure, sepsis)10930 daysGuan et al 2020 \[[@bib0060]\]109947 years old (33−67)Mortality\
Severity\
Complications (heart failure, kidney failure, sepsis)15In HospitalWang et al 2020 \[[@bib0065]\]10751 years old (36−65)Mortality\
Severity\
Evidence of co-infection\
Effectiveness of pharmacological therapy630 daysYang et al 2020 \[[@bib0070]\]5259.7 years (46.2−86.6)Mortality7In HospitalZhao et al 2020 \[[@bib0075]\]9146 years old (30−68)Mortality\
Severity\
Effectiveness of pharmacological therapy\
Need for mechanical ventilation\
Complications (heart failure, kidney failure, sepsis)7In HospitalZhou et al 2020 \[[@bib0080]\]19156 years old (46−67)Mortality\
Severity\
Complications (heart failure, kidney failure, sepsis)4430 daysTable 2Quality assessment of studies included through the Newcasttle-Ottawa scale (NOS).Table 2StudyRepresentative sampleSize of the sampleCourse of the informationOutcome not presented at the beginning of the studyControl of the confusion variableEvaluation of the outcomePeriod of monitoringTotal scale score Newcasttle OttawaChen et al 2020**★★★★★5/7**Grasselli et al 2020**★★★★★★★7/7**Guan et al 2020**★★★★★5/7**Wang et al 2020**★★★★★★6/7★★★★★★6/7**Zhao et al 2020**★★★★★5/7**Zhou et al 2020**★★★★★★6/7**Fig. 2Assessment of risk of bias using the ROBINS-I tool: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Fig. 2Fig. 3Forest plot for meta-analysis evaluating mortality risk in patients with a history of cerebrovascular disease and COVID-19.Fig. 3Fig. 4Funnel plot that evaluates risk of bias who presents symmetry, quantified in the Egger's test (Egger's test = -0.01 p = 0.0123).Fig. 4

4. Discussion {#sec0045}
=============

This systematic review reports an analysis of 7 retrospective observational studies showing the clinical characteristics of patients with disease caused by the SARSCOV-2 virus which were conducted in Wuhan, China \[[@bib0050],[@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080]\] and Lombardy, Italy patients with previous history of cerebrovascular disease and covid19 + showed an increase in mortality during the stay at hospital compared to patients with other type of comorbidity. Previous stroke's history was reported in all this studies with low heterogeneity (I^2^ = 49 %).

Agrawal et al. conducted a systematic review in which 6 studies were included to asses' mortality rates and severe form of disease in COVID19 patients, concluding that the previous history of cerebrovascular disease increased the risk of critical condition by 2,5 times; however, mortality didn't show a significant result \[[@bib0085]\]. In this review, the search strategy and the inclusion criteria were "COVID19" AND "Stroke" connectors, however the outcomes were not included. We did not include certain type of studies such as series of cases in our analysis to try to avoid bias in the quality of the design \[[@bib0090]\] ([Table 3](#tbl0015){ref-type="table"} ).Table 3Details Bias Risk Assessment using the ROBINS-1 tool for observational studies.Table 3EstudiosBias related to interventionBias of Lost DataBias of confusionBias in the outcomeBias of reportingBias of selectionRisk of global biasChen et al 2020LowHighModerateModerateLowLowModerateGrasselli et al 2020ModerateModerateLowLowLowLowLowGuan et al 2020LowLowLowLowLowLowLowWang et al 2020ModerateModerateLowModerateLowLowModerateYang et al 2020LowModerateLowLowLowLowLowZhao et al 2020LowHighLowLowLowLowLowZhou et al 2020LowLowLowLowModerateModerateLow

As limitations we found the small number of patients with a history of CVD, mainly in studies carried out in Wuhan, China. The type of included studies is a persistent limitation because they are all retrospective observational, therefore no clinical conclusions or factors can be drawn to establish this as a risk factor, lack of follow-up more than 30 days, evaluation of characteristics were not evaluated fundamental as is the cognitive and functional prognosis, however, due to the world situation given by this virus, there is a limitation of health resources, which include human talent, so establishing possible risk factors is important in the situation of Pandemic, since, it helps to optimize health resources. These findings could provide a basis for future risk scales in the care of patients with COVID19 in intensive care units or emergency services.

We considered that there is an important participation of the hemostatic system and disseminated intravascular coagulation that is present in sepsis and in patients affected by COVID19. Coronavirus produces endothelial damage, leading to an increase in mortality in patients with previous endothelial damage, which includes diabetics, cardiac patients, and with a history of cerebrovascular disease \[[@bib0095],[@bib0100]\].

5. Conclusions {#sec0050}
==============

The history of cerebrovascular disease is associated with a 2.78-fold increased risk of mortality compared to patients with other comorbidities or without underlying pathologies. However, prospective studies are needed, confirming cerebrovascular disease as a risk factor for COVID-19 mortality.

5.1. Summary of evidence {#sec0055}
------------------------

This systematic review gives an overview of the available literature on the role history stroke in the risk of mortality in COVID19 patients. This study only provides evidence 3b.

5.2. Limitations {#sec0060}
----------------

Our study has some limitations. Most studies focused largely on an experimental level. All articles included in this review are peer-reviewed. There is a possibility of publication bias.

Finally, the inclusion of only articles in English and Spanish could affect the generalization of our findings.
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